T601 + flucytosine

T601 + flucytosine is a combination antifungal therapy comprised of the investigational agent T601 (about which specific public details are not available in the provided search results) and **flucytosine**, a systemic antifungal medication in the antimetabolite agent class[1][7]. Flucytosine acts by disrupting fungal RNA and protein synthesis after entering the cell and being converted to 5-fluorouracil, ultimately leading to fungal cell death[1][7]. The combination regimen is intended to synergize antifungal effects and mitigate the development of drug resistance, paralleling the established clinical principle of combining flucytosine with other antifungals for invasive fungal infections[1][7]. Flucytosine is primarily indicated for severe **Candida** and **Cryptococcus** infections and is generally not used as monotherapy due to rapid resistance development[1][7]. No mechanism, modality, or clinical data are available for T601 itself in the provided results.

Other names

T601 + flucytosine